Trastuzumab, Pertuzumab

• Atezolizumab, Pertuzumab and Trastuzumab with chemotherapy as neoadjuvant treatment of HER2 positive early high-risk and locally advanced br… Pending
  2024-518026-32-00 Phase III 6 countries Fondazione Michelangelo
• Molecularly Tailored Therapy versus Standard Care in Advanced Pancreatic Cancer Pending
  2025-522431-34-00 Phase II 1 country Region Hovedstaden
• HER2DX-guided diagnostic treatment For patients with HER2-positive early-stage breast cancer Recruiting
  2025-521040-37-00 Phase III 4 countries Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques Augus…
• A randomized, open-label, phase II trial comparing neoadjuvant endocrine therapy in combination with trastuzumab, pertuzumab +/- the PI3K in… Recruiting
  2022-501152-28-00 Phase II 7 countries GBG Forschungs GmbH
• FINPROVE - The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs Recruiting
  2024-517478-68-01 Phase II 1 country HUS-Yhtymae
• A Study Evaluating the Efficacy and Safety of Inavolisib Plus Phesgo (pertuzumab, trastuzumab, and rHuPH20 injection for SC use) versus plac… Recruiting
  2022-502046-28-00 Phase III 7 countries F. Hoffmann-La Roche AG
• A Randomized Trial of Trastuzumab Deruxtecan and Biology-Driven Selection of Neoadjuvant Treatment for HER2-positive Breast Cancer Recruiting
  2022-501504-95-00 Phase II 3 countries Karolinska University Hospital
• Genomics guided targeted post-neoadjuvant therapy in patients with early breast cancer – a multicenter, open-label, umbrella phase-II study … Recruiting
  2024-514022-23-00 Phase II 1 country Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts
• TIME AND MOTION STUDY OF A SUBCUTANEOUS FIXED DOSE COMBINATION OF PERTUZUMAB AND TRASTUZUMAB FOR THE TREATMENT OF PATIENTS WITH HER2-POSITIV… Recruiting
  2023-509321-50-00 Phase III 1 country Roche Farma S.A.
• Improving public cancer care by implementing precision medicine in Norway Recruiting
  2023-507894-16-00 Phase II 1 country Oslo University Hospital HF
• A Multicenter, Open-Label, Single-Arm, Phase II Trial Exploring the Maintenance of Trastuzumab and Pertuzumab Following Trastuzumab Deruxtec… Ended
  2023-507306-13-00 Phase II 4 countries Medica Scientia Innovation Research S.L.
• A clinical trial to compare the effectiveness and safety of giredestrant with a subcutaneous combination of pertuzumab and trastuzumab versu… Ended
  2022-500014-26-00 Phase III 8 countries F. Hoffmann-La Roche AG
• A study of tucatinib versus placebo in combination with pertuzumab and trastuzumab for subjects with advanced or metastatic HER2+ breast can… Ended
  2023-503826-37-00 Phase III 12 countries Seagen Inc.
• Chemotherapy-Free pCR-Guided Strategy with subcutaneous trastuzumabpertuzumab and T-DM1 in HER2-positive early breast cancer (PHERGAIN-2) Ended
  2023-508738-32-00 Phase II 4 countries Medica Scientia Innovation Research S.L.
• A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Admi… Ended
  2023-506380-33-00 Phase III 3 countries F. Hoffmann-La Roche AG

Showing 1–15 of 15 trials